latest update:
[TrialBase DB]

trial summary · NCT07878988

This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

A Phase 1/1b, Muticenter Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors

Trial record from the TrialBase DB dataset, status RECRUITING, condition Colorectal Cancer, sponsored by LTZ Therapeutics, Inc.. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07878988phase PHASE1enrollment 152start 2026-12

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.

Source record: https://clinicaltrials.gov/study/NCT07878988

Facts

registry idNCT07878988
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionColorectal Cancer
sponsorLTZ Therapeutics, Inc.
sponsor classINDUSTRY
enrollment152
start date2026-12
primary completion2031-12
completion2031-12
results postednot reported

Conditions

  • Colorectal Cancer
  • Advanced/Metastatic Solid Tumor
  • Solid Tumor (Phase I)
  • EPCAM
  • Colon Cancer

Interventions

  • LTZ-232

Countries

  • United States

Intervention types: DRUG

Work with this record